BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2024 YTD Q3 P&L / Income Statement

2024-01-01 to 2024-09-30

Swipe to see the full flow
BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2024 YTD Q3 P&L / Income StatementIncome statement for 2024-01-01 through 2024-09-30. View: Product and service (Disaggregation of Revenue by Product and Region). Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETEliquisOpdivoRevlimidPomalyst/ImnovidOrenciaYervoyReblozylSprycelAbraxaneOpdualagBreyanziZeposiaCamzyosAbecmaSotyktuKrazatiAugtyroOther Growth productsOther Legacy productsTotal RevenuesGross profit (calculated)Cost of products soldOperating profit (calculated)Operating expenses (calculated)Acquired IPRDResearch and developmentAmortization of acquired intangible assetsMarketing, selling and administrativeOther (income)/expense, netEarnings/(loss) before income taxesNet earnings/(loss)Income tax provisionGross profit (calculated)Gross profit(calculated)$26.80 BOperating profit (calculated)Operating profit(calculated)−$8.55 BEarnings/(loss) before income taxesEarnings/(loss)before income taxes−$8.55 BTotal RevenuesTotal Revenues$35.96 BNet earnings/(loss)Net earnings/(loss)−$9.01 BEliquisEliquis$10.14 BOperating expenses (calculated)Operating expenses(calculated)$35.36 BOpdivoOpdivo$6.83 BIncome tax provisionIncome taxes$455.00 MRevlimidRevlimid$4.43 BAcquired IPRDAcquired IPRD$13.34 BPomalyst/ImnovidPomalyst/Imnovid$2.72 BCost of products soldCost of products sold$9.16 BResearch and developmentResearch and development$7.97 BOrenciaOrencia$2.68 BYervoyYervoy$1.86 BAmortization of acquired intangible assetsAmortization of acquiredintangible assets$7.18 BReblozylReblozyl$1.23 BMarketing, selling and administrativeMarketing, sellingand administrative$6.28 BSprycelSprycel$1.09 BOther (income)/expense, netOther (income)/expense, net$588.00 MAbraxaneAbraxane$701.00 MOpdualagOpdualag$674.00 MBreyanziBreyanzi$484.00 MZeposiaZeposia$408.00 MCamzyosCamzyos$379.00 MAbecmaAbecma$301.00 MSotyktuSotyktu$163.00 MKrazatiKrazati$87.00 MAugtyroAugtyro$23.00 MOther Growth productsOther Growth products$1.09 BOther Legacy productsOther Legacy products$675.00 M
Chart details

BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and service (Disaggregation of Revenue by Product and Region). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total Revenues
35,958,000,000 US dollars
Cost of products sold
9,156,000,000 US dollars
Gross profit (calculated)
26,802,000,000 US dollars
Operating expenses (calculated)
35,356,000,000 US dollars
Operating profit (calculated)
negative 8,554,000,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Earnings/(loss) before income taxes
negative 8,554,000,000 US dollars
Income tax provision
455,000,000 US dollars
Net earnings/(loss)
negative 9,009,000,000 US dollars
Opdivo
6,825,000,000 US dollars
Orencia
2,682,000,000 US dollars
Yervoy
1,855,000,000 US dollars
Reblozyl
1,226,000,000 US dollars
Opdualag
674,000,000 US dollars
Abecma
301,000,000 US dollars
Zeposia
408,000,000 US dollars
Breyanzi
484,000,000 US dollars
Camzyos
379,000,000 US dollars
Sotyktu
163,000,000 US dollars
Augtyro
23,000,000 US dollars
Krazati
87,000,000 US dollars
Other Growth products
1,093,000,000 US dollars
Eliquis
10,138,000,000 US dollars
Revlimid
4,434,000,000 US dollars
Pomalyst/Imnovid
2,722,000,000 US dollars
Sprycel
1,088,000,000 US dollars
Abraxane
701,000,000 US dollars
Other Legacy products
675,000,000 US dollars
Marketing, selling and administrative
6,278,000,000 US dollars
Research and development
7,968,000,000 US dollars
Acquired IPRD
13,343,000,000 US dollars
Amortization of acquired intangible assets
7,179,000,000 US dollars
Other (income)/expense, net
588,000,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
BRISTOL-MYERS SQUIBB COMPANY (BMY) FY2024 YTD Q3 P&L / Income Statement Sankey chart, Product and service (Disaggregation of Revenue by Product and Region) view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

74.5%

Gross profit / revenue

Operating margin

−23.8%

Operating profit / revenue

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!